PL4076652T3 - Farmaceutycznie dopuszczalna sól atrasentanu do zastosowania w sposobie leczenia nefropatii iga - Google Patents
Farmaceutycznie dopuszczalna sól atrasentanu do zastosowania w sposobie leczenia nefropatii igaInfo
- Publication number
- PL4076652T3 PL4076652T3 PL20903533.6T PL20903533T PL4076652T3 PL 4076652 T3 PL4076652 T3 PL 4076652T3 PL 20903533 T PL20903533 T PL 20903533T PL 4076652 T3 PL4076652 T3 PL 4076652T3
- Authority
- PL
- Poland
- Prior art keywords
- atrasentan
- treatment
- pharmaceutically acceptable
- acceptable salt
- iga nephropathy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949115P | 2019-12-17 | 2019-12-17 | |
| US202063005003P | 2020-04-03 | 2020-04-03 | |
| US202063072699P | 2020-08-31 | 2020-08-31 | |
| US202063084739P | 2020-09-29 | 2020-09-29 | |
| US202063125205P | 2020-12-14 | 2020-12-14 | |
| PCT/US2020/065311 WO2021126977A1 (en) | 2019-12-17 | 2020-12-16 | Methods of treating iga nephropathy with atrasentan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4076652T3 true PL4076652T3 (pl) | 2026-03-23 |
Family
ID=76478538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20903533.6T PL4076652T3 (pl) | 2019-12-17 | 2020-12-16 | Farmaceutycznie dopuszczalna sól atrasentanu do zastosowania w sposobie leczenia nefropatii iga |
Country Status (21)
| Country | Link |
|---|---|
| US (11) | US20210353593A1 (https=) |
| EP (2) | EP4076652B1 (https=) |
| JP (2) | JP7624995B2 (https=) |
| KR (1) | KR20230015874A (https=) |
| CN (3) | CN116327758A (https=) |
| AU (1) | AU2020404984A1 (https=) |
| BR (1) | BR112022012075A2 (https=) |
| CA (1) | CA3161516A1 (https=) |
| DK (1) | DK4076652T3 (https=) |
| FI (1) | FI4076652T3 (https=) |
| HR (1) | HRP20260121T1 (https=) |
| IL (1) | IL293921A (https=) |
| LT (1) | LT4076652T (https=) |
| MX (1) | MX2022007471A (https=) |
| PH (1) | PH12022551456A1 (https=) |
| PL (1) | PL4076652T3 (https=) |
| PT (1) | PT4076652T (https=) |
| RS (1) | RS67746B1 (https=) |
| SI (1) | SI4076652T1 (https=) |
| TW (1) | TWI875895B (https=) |
| WO (1) | WO2021126977A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230015874A (ko) | 2019-12-17 | 2023-01-31 | 치누크 세라퓨틱스, 인크. | 아트라센탄에 의해 iga 신장병증을 치료하는 방법 |
| CN114910647A (zh) * | 2022-05-07 | 2022-08-16 | 浙江大学 | 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用 |
| WO2023220930A1 (en) * | 2022-05-17 | 2023-11-23 | Increvet, Inc. | Veterinary pharmaceutical formulations cross-references to related applications |
| JP2025517355A (ja) * | 2022-05-19 | 2025-06-05 | チヌーク セラピューティクス，インコーポレイテッド | アトラセンタンを用いた巣状分節性糸球体硬化症の治療方法 |
| WO2024073672A1 (en) | 2022-09-30 | 2024-04-04 | Travere Therapeutics, Inc. | Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders |
| WO2024076177A1 (ko) * | 2022-10-05 | 2024-04-11 | 주식회사 대웅제약 | 이나보글리플로진을 포함하는 신장애 및/또는 당뇨병 예방 또는 치료용 약학 조성물 |
| EP4608396A1 (en) * | 2022-10-28 | 2025-09-03 | Chinook Therapeutics, Inc. | Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody |
| JP2025536433A (ja) | 2022-11-07 | 2025-11-05 | サンレノ セラピューティクス （シャンハイ） リミテッド | ＩｇＡ腎症を治療するためのエンドセリン受容体アンタゴニストとグルココルチコイドとの組み合わせ |
| WO2025261457A1 (zh) * | 2024-06-21 | 2025-12-26 | 深圳信立泰药业股份有限公司 | 内皮素a(eta)受体拮抗剂联用sglt-2抑制剂的医药用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5236940A (en) | 1988-12-15 | 1993-08-17 | Rhone-Poulenc Sante | Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US7208517B1 (en) | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
| US7365093B2 (en) | 1994-08-19 | 2008-04-29 | Abbott Laboratories | Endothelin antagonists |
| US6946481B1 (en) | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| US20020062121A1 (en) | 1995-05-16 | 2002-05-23 | Karl Tryggvason | Perfusion apparatus and methods for pharmaceutical delivery |
| ES2259803T3 (es) | 1996-02-13 | 2006-10-16 | Abbott Laboratories | Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina. |
| US20040191774A1 (en) | 2001-09-11 | 2004-09-30 | Moskowitz David W | Endothelin-1 promoter polymorphism |
| WO2003080038A1 (en) | 2002-03-22 | 2003-10-02 | Kissei Pharmaceutical Co., Ltd. | Preventive or therapeutic agent for kidney disease |
| AU2003226356A1 (en) | 2002-04-12 | 2003-10-27 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| US20030229906A1 (en) | 2002-04-15 | 2003-12-11 | Gelman Irwin H. | Methods and compositions for the treatment of disorders of HIV infection |
| US9388427B2 (en) | 2002-12-02 | 2016-07-12 | Biovec, Llc | In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors |
| US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
| DE602005022871D1 (de) | 2004-06-07 | 2010-09-23 | Univ Ramot | Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko |
| WO2006034234A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 3 of atrasentan hydrochloride |
| WO2006034085A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form of atrasentan hydrochloride |
| WO2006034094A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 1 of atrasentan hxdrochloride |
| CA2578824A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 2 of atrasentan hydrochloride |
| US8231907B2 (en) | 2006-03-21 | 2012-07-31 | Morehouse School Of Medicine | Nanoparticles for delivery of active agents |
| AU2007230580A1 (en) * | 2006-03-27 | 2007-10-04 | Genentech, Inc. | Methods for treating kidney disorders |
| WO2007119214A2 (en) | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| NZ578164A (en) | 2007-01-16 | 2011-12-22 | Musc Found For Res Dev | Compositions and methods for diagnosing, treating, and preventing prostate conditions |
| AU2008282773B8 (en) | 2007-07-31 | 2013-03-07 | Gilead Sciences, Inc. | Metabolites and derivatives of ambrisentan |
| EP2545920A1 (en) | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapy for complications of diabetes |
| US20120083421A1 (en) | 2008-10-16 | 2012-04-05 | The Trustees Of Columbia University In The City Of New York | Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan) |
| EP3708163A1 (en) | 2009-03-31 | 2020-09-16 | Ligand Pharmaceuticals, Inc. | Use of sparsentan for the treatment of chronic inflammatory diseases |
| EP2509594A1 (en) | 2009-12-09 | 2012-10-17 | INSERM - Institut National de la Santé et de la Recherche Médicale | Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis |
| US9255931B2 (en) | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| US9365445B2 (en) | 2010-07-28 | 2016-06-14 | Nippon Electric Glass Co., Ltd. | Method for producing phosphor-encapsulating capillary tube, phosphor-encapsulating capillary tube, wavelength-converting member, and method for producing wavelength-converting member |
| US20160015701A1 (en) * | 2013-03-08 | 2016-01-21 | Abbive Inc. | Methods of Treating Acute Kidney Injury |
| KR20160003128A (ko) | 2013-04-30 | 2016-01-08 | 애브비 인코포레이티드 | 아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법 |
| CA2916033C (en) * | 2013-07-08 | 2022-08-23 | Abbvie Inc. | Stabilized pharmaceutical dosage forms comprising atrasentan |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| US8962675B1 (en) | 2013-09-12 | 2015-02-24 | Abbvie Inc. | Atrasentan mandelate salts |
| JP2017534634A (ja) * | 2014-11-07 | 2017-11-24 | アッヴィ・インコーポレイテッド | 体液貯留の予測因子を使用してｃｋｄを処置する方法 |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| US20170014386A1 (en) | 2015-07-16 | 2017-01-19 | Abbvie, Inc. | Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children |
| MA43260A (fr) * | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme | Liants pd1 et/ou lag3 |
| US10736960B2 (en) | 2016-01-05 | 2020-08-11 | Omeros Corporation | Methods for inhibiting fibrosis in a subject in need thereof |
| JP2019530713A (ja) * | 2016-10-13 | 2019-10-24 | レトロフィン， インコーポレイテッド | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
| MX2021014356A (es) | 2016-11-23 | 2022-11-24 | Chemocentryx Inc | Metodo para tratar glomeruloesclerosis segmentaria focal. |
| AU2018347361A1 (en) | 2017-10-11 | 2020-04-30 | Chemocentryx, Inc. | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists |
| KR20260037123A (ko) | 2017-11-30 | 2026-03-17 | 이도르시아 파마슈티컬스 리미티드 | 엔도텔린 관련 질병의 치료를 위한 sglt-2 저해제와의 4-피리미딘설파미드 유도체의 병용 |
| KR20230015874A (ko) * | 2019-12-17 | 2023-01-31 | 치누크 세라퓨틱스, 인크. | 아트라센탄에 의해 iga 신장병증을 치료하는 방법 |
| US20220304979A1 (en) | 2019-12-17 | 2022-09-29 | Chinook Therapeutics, Inc. | Methods of reducing disease flares |
| JP2023521169A (ja) | 2020-04-10 | 2023-05-23 | チヌーク セラピューティクス，インコーポレイテッド | 糖尿病性腎疾患の処置方法 |
| US20220243994A1 (en) | 2021-02-04 | 2022-08-04 | Northrop Grumman Systems Corporation | Metal woodpile capillary wick |
-
2020
- 2020-12-16 KR KR1020227024511A patent/KR20230015874A/ko active Pending
- 2020-12-16 CA CA3161516A patent/CA3161516A1/en active Pending
- 2020-12-16 HR HRP20260121TT patent/HRP20260121T1/hr unknown
- 2020-12-16 WO PCT/US2020/065311 patent/WO2021126977A1/en not_active Ceased
- 2020-12-16 MX MX2022007471A patent/MX2022007471A/es unknown
- 2020-12-16 RS RS20260142A patent/RS67746B1/sr unknown
- 2020-12-16 LT LTEPPCT/US2020/065311T patent/LT4076652T/lt unknown
- 2020-12-16 PH PH1/2022/551456A patent/PH12022551456A1/en unknown
- 2020-12-16 CN CN202310043260.6A patent/CN116327758A/zh active Pending
- 2020-12-16 JP JP2022537007A patent/JP7624995B2/ja active Active
- 2020-12-16 AU AU2020404984A patent/AU2020404984A1/en active Pending
- 2020-12-16 PT PT209035336T patent/PT4076652T/pt unknown
- 2020-12-16 EP EP20903533.6A patent/EP4076652B1/en active Active
- 2020-12-16 CN CN202310043259.3A patent/CN116173014A/zh active Pending
- 2020-12-16 TW TW109144568A patent/TWI875895B/zh active
- 2020-12-16 IL IL293921A patent/IL293921A/en unknown
- 2020-12-16 DK DK20903533.6T patent/DK4076652T3/da active
- 2020-12-16 BR BR112022012075A patent/BR112022012075A2/pt unknown
- 2020-12-16 EP EP25219043.4A patent/EP4710928A3/en active Pending
- 2020-12-16 SI SI202030727T patent/SI4076652T1/sl unknown
- 2020-12-16 CN CN202080007568.XA patent/CN113272013A/zh active Pending
- 2020-12-16 FI FIEP20903533.6T patent/FI4076652T3/fi active
- 2020-12-16 PL PL20903533.6T patent/PL4076652T3/pl unknown
-
2021
- 2021-06-30 US US17/363,604 patent/US20210353593A1/en not_active Abandoned
-
2022
- 2022-05-27 US US17/826,753 patent/US20220304978A1/en not_active Abandoned
- 2022-05-27 US US17/826,843 patent/US11491137B2/en active Active
- 2022-05-27 US US17/826,832 patent/US20220288026A1/en not_active Abandoned
- 2022-08-16 US US17/888,766 patent/US12582631B2/en active Active
-
2023
- 2023-07-18 US US18/223,340 patent/US11998526B2/en active Active
- 2023-07-18 US US18/223,290 patent/US20230355579A1/en not_active Abandoned
- 2023-07-18 US US18/223,355 patent/US12121509B2/en active Active
- 2023-11-29 US US18/523,609 patent/US12521369B2/en active Active
-
2024
- 2024-09-13 US US18/884,802 patent/US20250281454A1/en active Pending
- 2024-12-12 JP JP2024218275A patent/JP7821870B2/ja active Active
- 2024-12-20 US US18/990,351 patent/US12370174B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4076652T3 (pl) | Farmaceutycznie dopuszczalna sól atrasentanu do zastosowania w sposobie leczenia nefropatii iga | |
| LT3947375T (lt) | Imidazolonilchinolino junginiai ir jų terapinis panaudojimas | |
| IL261721A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| LT3472153T (lt) | Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme | |
| MX375639B (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk | |
| DK4014976T3 (da) | Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan | |
| EP3870284C0 (en) | ADJUSTABLE THERAPEUTIC FACE MASK | |
| PL3806898T3 (pl) | Antagonista gremlin-1 do zastosowania w leczeniu nowotworu | |
| PL3972643T3 (pl) | Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych | |
| PL3556377T3 (pl) | Dalargin do stosowania w leczeniu ostrych infekcji wirusowych dróg oddechowych | |
| PL3592355T3 (pl) | Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| IL281100A (en) | Methods of modulating m2 macrophage polarization and use of same in therapy | |
| PL3732294T3 (pl) | Tymohydrochinon do stosowania w leczeniu hiperglikemii | |
| GB2587172B (en) | Pyronaridine or pharmaceutically acceptable salts thereof for the treatment of cancer | |
| PL3679034T3 (pl) | Pochodne 1-(4-(izoksazol-5-ilo)-1h-pirazol-1-ilo)-2-metylo-propan-2-olu i związki pokrewne jako inhibitory il-7 i ifn-gamma do leczenia chorób autoimmunologicznych i przewlekłego zapalenia | |
| IL257876A (en) | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders | |
| IL263804A (en) | Wnt inhibitors for use in the treatment of fibrosis | |
| PL3697399T3 (pl) | Środki terapeutyczne do zastosowania w leczeniu zespołu niespokojnych nóg | |
| IL258610B (en) | Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer | |
| IL286818A (en) | Mirikizumab for use in a method of treating crohns disease | |
| HUE066609T2 (hu) | Adagolási forma betegség kezelésében vagy megelõzésében történõ alkalmazásra | |
| ECSP16078100A (es) | Nuevo uso de n,n -2-bis- mercaptoetil isoftalamida | |
| PT3322438T (pt) | Inibidores de il-8 para utilização no tratamento de determinados distúrbios urológicos | |
| ZA202206272B (en) | 2-amino-n-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use |